Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

TSXV:BTI.H - Post Discussion

biOasis Technologies Ord Shs > Stagliano's Neuron23 Raises Another $100 million
View:
Post by JDavenport on Mar 30, 2022 4:42pm

Stagliano's Neuron23 Raises Another $100 million

Former Bioasis director Nancy Stagliano's company, privately-held Neuron23 Inc., has raised another US$100 million and has announced two small-molecule preclinical drugs. One of the drugs, NEU-723, is a small molecule that can cross the blood-brain barrier and "...targets LRRK2, a Parkinson’s disease and inflammatory disease-linked gene..."
 
This is the same gene that is targeted in the Biogen/Denali agreement announced in October of 2020.
 
Neuron23 uses chemical design technologies such as artificial intelligence to create small molecules that can target many diseases including neurological disorders. Small molecules can be designed to either cross the BBB or not. The manufacturing of small molecules is a chemical process, not a biological one, meaning that the small molecules do not require the significant cell-line manufacturing infrastructure that biologics require. You can read more about small-molecules vs biologics << here >>.
 
The advantage that Bioasis has with respect to the BBB is that xB3 appears to be able to transport almost any drug across the BBB. This means that the payload drug can be designed with no compromises with respect to transport across the BBB. xB3 does all the work of delivery across the BBB and the payload, no matter its size, does the disease treatment.
 
Small molecule drugs have to be designed to work and to be small, a compromise that is not always the most advantageous with respect to efficacy. 
 
Neuron23's press release can be found << here >>.You can find the Endpoints News coverage of the story << here >>. Fierce Biotech covers it << here >>
 
One of the companies participating in the financing of Neuron23 is Westlake Village BioPartners where Dr. Stagliano was previously an advisor.
 
jd
Comment by beenthere on Mar 30, 2022 6:33pm
JD, why do you post this stuff? You are getting as bad as chrispi!! Do you somehow think this helps Bioasis? To me and I am sure Others agree with me it just makes us look worst than ever! Is this how you are getting back at BTI and DrDR?
Comment by Finallytherock on Mar 30, 2022 6:45pm
He's so desperate to show anything with this company that he's resorting to posting things unrelated to bioasis. There's nothing to say here. Not sure what the company was paying JD for given that there's nothing to say. 
Comment by lovingold on Mar 31, 2022 3:07pm
Who is paying you Finallytherock (someone who owns zero, nada, none, 0 shares in Bioasis) for your constant bashing of the company and its shareholders and former employees? Someone should not have enough free time as you clearly do, for something that they shouldn't, theoretically, have a care or concern about. Hence, you must have an ulterior motive. Alas, you are a paid troll or want ...more  
Comment by Finallytherock on Apr 01, 2022 9:53am
want cheap shares? i think the shares are cheap enough, lol
Comment by JDavenport on Mar 30, 2022 6:54pm
I posted this because Neuron23 is an advanced technology company that will get drugs into the brain. Neuron23 is important enough that Endpoints News and others presented it as a competitor to the Denali/Biogen LRRK2 project. That was Endpoints headline. That means that Neuron23 is certainly a Bioasis competitor. But Denali, Biogen and Bioasis also understand that they're also strong ...more  
Comment by Aarcor on Mar 30, 2022 7:07pm
Thanks for posting JD.  Other management teams in the same space can garner large amounts of cash to fund their objectives, while Rathjen struggles to get 1% of that. Neuron23 or whatever its called will plot its own course and control its own destiny. And of course, another reminder, that the longer BTI produces no publishable advancements, the larger the threat to the company's one ...more  
Comment by JDavenport on Mar 30, 2022 7:14pm
Aarcor, Neuron23 picked up an equity investment. Bioasis shareholders have made it clear that they don't want DrDR to do highly dilutive equity financings. She has followed the shareholders directives on that. As a result, Bioasis has to rely on bridge loans, the Lind funding and business deals, the Chiesi being one of those. So shareholders can't complain about a private company raising ...more  
Comment by Finallytherock on Mar 30, 2022 7:27pm
How are things going with chiesi? Almost 2 years and no updates? Hopefully it goes better than the prothena deal 
Comment by beenthere on Mar 30, 2022 7:37pm
JD, actually I was referring to the raise amounts! Bioasis.   ...... $ 200 000 Neuron23. .... $ 100 000 000 Simply laughable!  I'm embarrassed to say I own BTI stock! Something has to change if BTI is ever going to be taken seriously.
Comment by Finallytherock on Mar 30, 2022 7:38pm
Aren't they exploring strategic alternatives?
Comment by lovingold on Mar 31, 2022 2:59pm
Finallytherock, your ignorance of the capital markets is not suprising. Geez. As another poster usually writes "give your head a shake man". https://www.forbes.com/sites/joecornell/2022/02/22/ncr-corp-to-explore-strategic-alternatives-for-its-business-units/?sh=742627564096   https://www.prnewswire.com/news-releases/treehouse-foods-exploring-strategic-alternatives-to-maximize-value ...more  
Comment by lovingold on Mar 31, 2022 3:00pm
Finallytherock, your ignorance of the capital markets is not suprising. Geez. As another poster usually writes "give your head a shake man". https://www.forbes.com/sites/joecornell/2022/02/22/ncr-corp-to-explore-strategic-alternatives-for-its-business-units/?sh=742627564096   https://www.prnewswire.com/news-releases/treehouse-foods-exploring-strategic-alternatives-to-maximize-value ...more  
Comment by JDavenport on Mar 30, 2022 7:43pm
I agree, beenthere. You should be embarrassed to own Bioasis stock. You don't know anything about Bioasis.  jd
Comment by Finallytherock on Mar 30, 2022 7:45pm
JD doesn't own any stock. He had to sell his shares to pay for basic necessities. Stock was essentially worthless 
Comment by beenthere on Mar 30, 2022 8:04pm
I know it has something to do with BBB whatever that is! And it has lost a lot  of money for it's investors! And hasn't been able to achieve anything in the last 10 years plus! And it  probably has the best do nothing management in the market! Should I continue?
Comment by JDavenport on Mar 30, 2022 8:15pm
Yes. Continue, beenthere. Which management? Look, the 10 years, 14 actually, are owned by the oldest management, not the current one. That amount of time has done us damage. No question. It's also allowed some very formidable technologies to advance. That's one of the most important points of my earlier Neuron23 post.  It's no problem for me to write a very negative story ...more  
Comment by beenthere on Mar 30, 2022 8:22pm
It's also not a problem to write a very positive story about Bioasis. I have no doubt JD that you would do that but it would  be either " fiction" or in the year 2032!
Comment by JDavenport on Mar 30, 2022 8:24pm
beenthere says, "It's also not a problem to write a very positive story about Bioasis. I have no doubt JD that you would do that but it would  be either " fiction" or in the year 2032!" That's nonsense, beenthere. You can do better. jd
Comment by beenthere on Mar 30, 2022 9:42pm
JD you are so so predictable aren't you? When I or anyone else have you stumped you always say the same thing! " You can do better" Well JD here is back to you! YOU can do better!
Comment by JDavenport on Mar 30, 2022 9:52pm
You have never stumped me, beenthere. What an illusion! Yes. I can do better, but I'm starting somewhere way higher than you. And remember, you have admitted that you don't read my posts. Your responses are, therefore, dog whistles only, nothing of substance and everybody knows it. Maybe you're right. Maybe you can't do better. jd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities